October 15, 2008 – Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent (DES) from Medtronic Inc. is associated with statistically fewer heart attacks than Boston Scientific’s Taxus DES.

Martin B. Leon, M.D., founder and chairman emeritus of the Cardiovascular Research Foundation and principal investigator of ENDEAVOR-IV, presented the results at TCT 2008.

October 15, 2008 – At TCT 2008, Boston Scientific Corp. announced 12-month left main and three-vessel disease subset data from its landmark SYNTAX trial comparing percutaneous coronary intervention (PCI) using the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System to contemporary coronary artery bypass graft (CABG) surgery.

October 15, 2008 - The new name and branding for MEDRAD’s interventional products division was unveiled to the public at TCT 2008 under the name MEDRAD Interventional/Possis.

October 15, 2008 - Boston Scientific Corp. announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based on preliminary data from Millennium Research Group (MRG), a provider of strategic information to the healthcare sector.

Based on the MRG data, the company estimates its share percentages of the U.S. DES market for September as follows:

- Boston Scientific’s PROMUS Everolimus-Eluting Coronary Stent System: 25 percent

- Boston Scientific’s TAXUS Express2 Paclitaxel-Eluting Coronary Stent System: 19 percent

October 15, 2008 - At TCT 2008, Philips Healthcare is showcasing cath lab improvements, designed to present users with seamless interaction between image acquisition and visualization technologies, hemodynamic monitoring and charting, cath lab and statistical reporting, and multimodality image access, viewing and storage.

October 15, 2008 - Julio Palmaz, M.D. made his mark on the medical world 20 years ago with the invention of the stent which revolutionized cardiac care, and now more than a million people each year undergo coronary artery stenting to repair clogged arteries.

October 14, 2008 - St. Jude Medical Inc. said today at TCT 2008 that the FDA and European CE Mark approval of the Angio-Seal Evolution Vascular Closure Device.

October 14, 2008 - At TCT 2008, Philips will showcase CT Comprehensive Cardiac Analysis (CCA) with 3D-QCA, which is used to perform detailed evaluation of the coronary arteries and advanced ventricular functional analysis.

Designed to help hospitals integrate CT directly with interventional cardiovascular procedures, Philips Brilliance CT's Comprehensive Cardiac Analysis (CCA) package uses a 3D CT segmentation of the coronary tree to select and visualize the best 2D C-arm projections for use in planning for percutaneous coronary interventional (PCI) procedures.

October 15, 2008 - Philips is showing for the first time at TCT, the CX50 CompactXtreme ultrasound system, which brings premium technologies from the Philips iE33 system to a compact form.

October 14, 2008 - CoreValve said the expanded clinical evaluation of its ReValving System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace.

More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now